Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ExpreS2ion Biotechnologies and the Jenner Institute, University of Oxford Enter a Licensing Agreement

Published: Monday, October 15, 2012
Last Updated: Monday, October 15, 2012
Bookmark and Share
License agreement for the ExpreS2 technology platform.

ExpreS2ion Biotechnologies has announced that they have signed a research license agreement to provide the University of Oxford access to ExpreS2ion's Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production.

The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford.

The platform will be used by various research teams to address expression of complex and "difficult-to-make" proteins.

This license is a perfect example of ExpreS2ion Biotechnologies' vision of making its production platform available to academic centers of excellence globally, in complement to the Company's strategy of making S2 one of the standard protein production platforms in the vaccine and therapeutic protein segments.

Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies, said: "We are delighted that the Jenner Institute at Oxford University has taken a Research License to our proprietary ExpreS2 platform for protein expression. The ExpreS2 platform has shown to provide a way forward to projects with a need for a robust and fully scalable protein production platform, such as certain challenging recombinant subunit vaccine projects.

ExpreS2ion is proud to enter this Agreement with the University of Oxford, one of the world's most prestigious Universities, with well-established, world-recognized medical research."

Dr. Simon Draper, a MRC Research Fellow, commented: "access to the ExpreS2 platform at the Jenner Institute in Oxford will greatly expand our protein vaccine production capabilities. We are looking forward to working with ExpreS2ion Biotechnologies as we develop new clinically-relevant protein vaccines to target difficult pathogens, such as malaria."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A Vaccine Against Placental Malaria Made with ExpreS2
ExpreS2ion Biotechnologies’ protein expression technology is ready to start human tests in Germany and Benin.
Saturday, March 21, 2015
LMU Munich and ExpreS2ion Biotechnologies Enter a Licensing Agreement
Agreement for use of the ExpreS2 technology platform.
Tuesday, February 24, 2015
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!